Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AVBP vs ACHV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACHV Captures Overall Composite Edge (56.6 HOLD vs 43.7 HOLD), While AVBP Leads 3–1 on Growth & Valuation Pillars

ACHV Overall Winner 6-Pillar Tally: AVBP 3 – 1 ACHV (2 Tie) Matrix Metrics: AVBP 1 – 7 ACHV

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over ArriVent BioPharma, Inc. (AVBP) on higher Unified Composite conviction (56.6/100 HOLD vs. 43.7/100 HOLD) after splitting the core matrix 7–1 (led by Valuation Multiples), while AVBP wins 3–1 across the 6-pillar growth and valuation breakdown. AVBP trades at $11.98 (N/M Forward P/E, -3620.0% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. AVBP 43.7/100 HOLD) and 1.73β · 62% Vol risk profile, whereas AVBP leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AVBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8); meanwhile ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVBP vs ACHV
AVBP NASDAQ
ArriVent BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$11.98
-7.92% 1D
Market Cap $676.0M
TTM Revenue $5.0M
Forward P/E N/M
Beta / 30D Vol 1.27β · 128% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 33.0 Fund 57.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.5%), weak momentum, RSI 31
RSI-14: 30.8 · SMA20: $15.02 · SMA50: $20.98
ACHV NASDAQ Head-to-Head Winner
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
TTM Revenue N/A
Forward P/E 35.3x
Beta / 30D Vol 1.73β · 62% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $6.72 · SMA50: $7.28

6-Pillar Scorecard Institutional Category Breakdown (AVBP 3 – 1 ACHV)

Columns: Metric · AVBP · ACHV
1. Valuation Multiples ACHV
Forward P/E N/M 35.3x
Trailing P/E N/M 35.3x
PEG Ratio N/M 17.68x
EV / Revenue 112.5x N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.0M N/A
Market Cap $676.0M $692.8M
3. Profitability & Quality AVBP
Gross Margin 100.0% N/A
Operating Margin -3620.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -48.7% -845.0%
4. Balance Sheet & Cash Flow AVBP
Cash Generation (TTM) -$153M -$44M
Cash Flow Margin N/A N/A
Net Cash / Leverage $113M Net Cash $46M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVBP
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile 88.5% (6th %ile) 88.3% (23rd %ile)
Put/Call OI Skew 0.16x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVBP (1) vs ACHV (7)
Institutional Metric AVBP ACHV Criterion Row Edge
Market Capitalization
Scale
$676.0M $692.8M Larger Scale ACHV
Trailing P/E Ratio
Valuation
N/M 35.3x Lower Multiple ACHV
Forward P/E Ratio
Valuation
N/M 35.3x Lower Multiple ACHV
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-3620.0% 0.0% Higher Margin ACHV
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-48.7% -845.0% Higher ROE AVBP
52-Week Range Position
Momentum
2% ($11–$36) 69% ($3–$9) Stronger Trend ACHV
Beta / 30D Volatility
Risk Regime
1.27β · 128% Vol 1.73β · 62% Vol Lower Realized Risk ACHV
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ACHV
Trailing 12M Revenue (USD)
Operating Scale
$5.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 112.5x EV/Rev 17.68x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$153M ($113M Net Cash) -$44M ($46M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACHV +6.86 pp
AVBP: -15.36% · ACHV: -8.5%
3M Horizon ACHV +55.04 pp
AVBP: -54.89% · ACHV: +0.15%
6M Horizon ACHV +72.5 pp
AVBP: -51.21% · ACHV: +21.29%
1Y Horizon ACHV +76.08 pp
AVBP: -28.05% · ACHV: +48.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVBP vs ACHV. Trailing 12-month operating profitability (AVBP -3620.0% vs ACHV 0.0%) and valuation multiples (AVBP N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

AVBP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.0M
Gross Margin100.0%
Op. Margin-3620.0%
ROE / Fwd P/E-48.7% · N/M
ACHV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-845.0% · 35.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVBP BREAKDOWN
102d in phase · OBV ACCUMULATION
Current IV 88.5%
IV Percentile 6th %ile
Put/Call OI Skew 0.16x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact AVBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase · OBV NEUTRAL
Current IV 88.3%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACHV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $676.0M market capitalization and -3620.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACHV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVBP vs ACHV Key Questions & Quantitative Answers

As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over ArriVent BioPharma, Inc. (AVBP) on higher Unified Composite conviction (56.6/100 HOLD vs. 43.7/100 HOLD) after splitting the core matrix 7–1 (led by Valuation Multiples), while AVBP wins 3–1 across the 6-pillar growth and valuation breakdown. AVBP trades at $11.98 (N/M Forward P/E, -3620.0% operating margin) versus ACHV at $6.78 (35.3x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. AVBP 43.7/100 HOLD) and 1.73β · 62% Vol risk profile, whereas AVBP leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.8); meanwhile ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVBP and ACHV split Growth & Scale metrics: AVBP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $5.0M TTM revenue (100.0% gross margin, -3620.0% operating margin), compared with ACHV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AVBP generates $5.0M in USD-normalized revenue versus N/A for ACHV. In operating R&D and SG&A reinvestment, AVBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACHV.

ACHV screens cheaper on headline valuation multiples. AVBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 112.5x EV/Revenue (unreported FCF margin), whereas ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVBP (-48.7% ROE) versus ACHV (-845.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AVBP carries 88.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.27β · 128% Vol realized risk). By comparison, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.